Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romanski, A
Right arrow Articles by Ottmann, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Romanski, A
Right arrow Articles by Ottmann, O.
Haematologica, Vol 89, Issue 4, 419-426
Copyright © 2004 by Ferrata Storti Foundation


Journal Article

Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia

A Romanski, B Bacic, G Bug, H Pfeifer, H Gul, S Remiszewski, D Hoelzer, P Atadja, M Ruthardt, and OG Ottmann

Med. Klinik III/Abtl. Hamatologie, Johann Wolfgang Goethe-Universitat, 60590 Frankfurt, Germany.

BACKGROUND AND OBJECTIVES: Chromatin structure and thereby transcription is controlled by the level of acetylation of histones, which is determined by the balance between histone acetyl transferase (HAT) activity and histone deacetylase (HDAC) activity. HDAC inhibitors are a class of compounds able to regulate gene expression by modulating chromatin structure. There are two major classes of HDAC inhibitors: the hydroxamic acid derivatives such as trichostatin A (TSA) or SAHA, and the butyrates such as phenyl-butyrate. HDAC inhibitors interfere with differentiation, proliferation and apoptosis in tumor cells. Here, we investigated the activity of a new hydroxamic acid derivative, LAQ824, on lymphoblastic cells. DESIGN AND METHODS: Four different pre-B lymphoblastic cell lines: Sup-B15 and TMD-5, both t(9;22) positive, SEM, t(4;11) positive, and NALM-6 cells were exposed to the hydroxamic acid derivatives, LAQ824 and TSA. Histone hyperacetylation, apoptosis, cell cycle and related pathways were assessed by flow cytometry and Western blotting. RESULTS: LAQ824 significantly inhibited the proliferation of leukemic lymphoblastic cell lines. The effect of LAQ824 was due to increased apoptosis accompanied by activation of caspase-3 and caspase-9, cleavage of poly(ADP-ribose)-polymerase (PARP) as well as by down-regulation of Bcl-2 and disruption of the mitochondrial membrane potential. Surprisingly, LAQ824-induced apoptosis was at least partially independent of caspase activation as indicated by the fact that LAQ824-induced apoptosis was inhibited only partially in both t(9;22) positive Sup-B15 and TMD-5 cells, whereas no inhibition was observed in t(4;11) positive SEM cells upon exposure to the polycaspase inhibitor zVAD-fmk. INTERPRETATION AND CONCLUSIONS: Our study establishes that LAQ824 is a promising agent for the therapy of acute lymphoblastic leukemia.


This article has been cited by other articles:


Home page
BloodHome page
A. Scuto, M. Kirschbaum, C. Kowolik, L. Kretzner, A. Juhasz, P. Atadja, V. Pullarkat, R. Bhatia, S. Forman, Y. Yen, et al.
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells
Blood, May 15, 2008; 111(10): 5093 - 5100.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. M. Lee, J. H. Bae, M. J. Kim, H. S. Lee, M. K. Lee, B. S. Chung, D. W. Kim, C. D. Kang, and S. H. Kim
Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1084 - 1092.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Kato, B. C. Salumbides, X.-F. Wang, D. Z. Qian, S. Williams, Y. Wei, T. B. Sanni, P. Atadja, and R. Pili
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
Mol. Cancer Ther., January 1, 2007; 6(1): 70 - 81.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Puccetti, X. Zheng, D. Brambilla, A. Seshire, T. Beissert, S. Boehrer, H. Nurnberger, D. Hoelzer, O. G. Ottmann, C. Nervi, et al.
The Integrity of the Charged Pocket in the BTB/POZ Domain Is Essential for the Phenotype Induced by the Leukemia-Associated t(11;17) Fusion Protein PLZF/RAR{alpha}
Cancer Res., July 15, 2005; 65(14): 6080 - 6088.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
G. Bug, H. Gul, K. Schwarz, H. Pfeifer, M. Kampfmann, X. Zheng, T. Beissert, S. Boehrer, D. Hoelzer, O. G. Ottmann, et al.
Valproic Acid Stimulates Proliferation and Self-renewal of Hematopoietic Stem Cells
Cancer Res., April 1, 2005; 65(7): 2537 - 2541.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. G. Catalano, N. Fortunati, M. Pugliese, L. Costantino, R. Poli, O. Bosco, and G. Boccuzzi
Valproic Acid Induces Apoptosis and Cell Cycle Arrest in Poorly Differentiated Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1383 - 1389.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.